The Medicines Company (MDCO): A Sensible Acquisition by This Healthcare Company

Page 1 of 2

As competition gets stronger, companies attempt to consolidate operations. Although this consolidation is an expensive way to penetrate the market, in the pharmaceutical industry, this method brings safer growth. The smaller players especially are aiming to integrate with those who have their products in the second or third phases of clinical trials.

The Medicines CompanyThat same strategy has been used by The Medicines Company (NASDAQ:MDCO). After passing the last stage of clinical trials for Fibrocaps, it has announced the acquisition of ProFibrix for $90 million. Fibrocaps, a dry powder topical formulation of fibrinogen and thrombin, is a newly discovered treatment for surgical bleeding.

719 patients were studied during the trial. The trial fulfilled all the requirements of primary and secondary hemostasis efficacy endpoints in spinal surgery, hepatic resection, soft tissue surgery, and vascular surgery. A complimentary dry powder spray has also been developed.

Fibrocaps is a significant advancement in the drug industry. Due to its ease of use and effectiveness, along with the complimentary spray device, it has the potential to constitute a crucial development in surgical hemostasis. Through this integration, the company will be able to expand its operations in the surgical field and strengthen its global management team. It will also allow it to work with U.S. surgery centers and enter the European market.

Revenue is anticipated to increase by $300 million after the acquisition. Last year, sales for The Medicines Company (NASDAQ:MDCO) were $559 million, so if approved in primary markets, Fibrocaps will add more than 45% to existing revenue. The cost for the acquisition is expected to be $9 million to $12 million, which will be felt in the third quarter.

The company’s revenue has increased by 25% in the first half of this year. Its adjusted net income, excluding onetime costs, was 64% higher than the previous year. Its net margin and the debt-to-equity ratio are considerably better than the overall industry.

Competitor strategies

In July, Endo Health Solutions Inc (NASDAQ:ENDP) announced the launch of its MiniArc Pro single-incision sling system. The system is used for the treatment of female stress urinary incontinence (SUI). This product will boost revenue as SUI disease is  increasing in the U.S.

Currently, there are more than 13 million women suffering from this disease. The system is an upgrade to two previous systems, which have shown a success rate of 85% to 90% percent across multiple studies. It gives physicians the ability to measure sling tension in a repeatable way to help find the most accurate placement for patients. As many SUI tests are painful and make the patients uncomfortable, this new way of accurate insertion will reduce pain and increase comfort level.

In the first quarter of 2013, Endo Health Solutions Inc (NASDAQ:ENDP)’ sales increased by 3% while its adjusted per share earnings increased by 25% year-over-year. The company anticipates 2013 revenue to be in the range of $2.80 billion to $2.95 billion, and expected earnings to be in the range of $2.10 to $2.40. In 2012, it endured a per-share loss of $6.40, which means the company is making a significant recovery.

Largest comp

Pfizer Inc. (NYSE:PFE) has announced it will internally separate its business into three segments; two relating to innovative business lines and the third including a value business line. All three segments include developed and emerging markets. Each of these segments will operate as a separate global business.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!